Biomarker Testing Market Report 2026

Biomarker Testing Market Overview

• Biomarker Testing market size has reached to $19.75 billion in 2025 • Expected to grow to $35.51 billion in 2030 at a compound annual growth rate (CAGR) of 12.4% • Growth Driver: Rising Cancer Burden Fueling The Growth Of The Market Due To Increasing Incidence Driven By Lifestyle Factors • Market Trend: Innovative IHC Technology Supports Precise Cancer Grading And Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Biomarker Testing Market?

Biomarker testing refers to the analysis of blood, tissue, or other body fluids to identify specific biological markers that reflect normal or diseased conditions. It plays a crucial role in diagnosing diseases, predicting their progression, and tailoring personalized treatment plans. The main product types of biomarker testing include consumables, instruments, services, and others. Consumables are items that are used up or depleted through use and need to be replaced regularly, such as food, medical supplies, or office materials. The technologies utilized include polymerase chain reaction (PCR), next-generation sequencing (NGS), immunoassays, and others. Biomarker testing finds application in oncology, cardiology, neurology, infectious diseases, and others, serving key end-users spanning hospitals, diagnostic laboratories, research institutes, and others.

What Is The Biomarker Testing Market Growth Forecast?

The biomarker testing market size is expected to see rapid growth in the next few years. It will grow to $35.51 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to increasing investments in personalized medicine, rising use of biomarkers in drug development, expansion of oncology and infectious disease testing, growing demand for minimally invasive diagnostics, advancements in multi-omics technologies. Major trends in the forecast period include increasing adoption of precision medicine diagnostics, rising use of companion diagnostics, growing integration of ai in biomarker analysis, expansion of liquid biopsy testing, enhanced focus on early disease detection.

Global Biomarker Testing Market Segmentation

1) By Product Type: Consumables, Instruments, Services 2) By Technology: Polymerase Chain Reaction, Next-Generation Sequencing, Immunoassays, Other Technologies 3) By Application: Oncology, Cardiology, Neurology, Infectious Diseases, Other Applications 4) By End-User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users Subsegments: 1) By Consumables: Reagents, Assay Kits, Sample Collection Devices, Chemicals And Buffers 2) By Instruments: Polymerase Chain Reaction (PCR) Systems, Next-Generation Sequencing (NGS) Platforms, Microarray Systems, Mass Spectrometry Instruments, Immunoassay Analyzers 3) By Services: Biomarker Discovery Services, Diagnostic Testing Services, Companion Diagnostic Development, Clinical Trial Testing Services, Contract Research Organization (CRO) Services

What Is The Driver Of The Biomarker Testing Market?

The rising cancer burden is expected to propel the growth of the biomarker testing market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rising cancer burden is due to lifestyle choices such as poor diet, smoking, physical inactivity, and excessive alcohol consumption. Biomarker testing enhances cancer detection by enabling early and precise identification of disease-specific markers, improving diagnostic accuracy. It supports personalized treatment plans, leading to better patient outcomes and more effective healthcare management. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, around 165,000 new cancer cases were diagnosed in 2023, with projections indicating that approximately 204,000 cases will be diagnosed annually by 2033, contributing to an estimated total of 1.9 million cancer cases between 2024 and 2033. Therefore, the rising cancer burden is driving the growth of the biomarker testing industry.

Key Players In The Global Biomarker Testing Market

Major companies operating in the biomarker testing market are Roche Diagnostics International Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers AG, Becton Dickinson and Company, GE HealthCare Technologies Inc., Agilent Technologies Inc., Illumina Inc., Hologic Inc., Charles River Laboratories International Inc., PerkinElmer Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Myriad Genetics Inc., Guardant Health Inc., Sino Biological Inc., Proteome Sciences plc

Global Biomarker Testing Market Trends and Insights

Major companies operating in the biomarker testing market are focusing on developing technologically advanced solutions, such as immunohistochemistry (IHC) technology, to improve diagnostic accuracy, enable early disease detection, and support personalized treatment strategies. Immunohistochemistry (IHC) technology is a laboratory technique that uses antibodies to detect specific proteins in tissue samples, helping identify and visualize biomarkers for disease diagnosis and research. For instance, in July 2023, Quest Diagnostics Incorporated, a US-based medical laboratories company, launched a new tissue-based prostate cancer biomarker test through its AmeriPath business to enhance diagnostic accuracy using proprietary biomarkers EV1, EV2, and EV3. This test addresses a critical clinical need by helping physicians more precisely identify and differentiate aggressive forms of prostate cancer, improving grading consistency, and guiding appropriate treatment strategies for patients.

What Are Latest Mergers And Acquisitions In The Biomarker Testing Market?

In August 2025, Quanterix Corp., a US-based life sciences company, acquired Emission Inc. for approximately $70 million. With this acquisition, Quanterix aims to expand its technology portfolio and market reach by integrating Emission's advanced multiplex and multi-omic assay technologies, thereby strengthening its position in the biomarker testing sector and driving growth through enhanced diagnostic capabilities and new market opportunities. Emission Inc. is a US-based biotechnology company offering multiplex and multi-omic assay solutions for biomarker testing.

Regional Outlook

North America was the largest region in the biomarker testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Biomarker Testing Market?

The biomarker testing market consists of revenues earned by entities by providing services such as clinical biomarker testing services, bioinformatics and data analysis services, sample collection and biobanking services, and companion diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The biomarker testing market includes sales of analytical instruments, imaging devices, lab-on-a-chip and microfluidic devices, and data acquisition and integration hardware. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Biomarker Testing Market Report 2026?

The biomarker testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biomarker testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.